Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Prognostic value of blood-based biomarkers in predicting progression to dementia from SCD/MCI

Madison Honey, PhD candidate, Amsterdam University Medical Centre, Amsterdam, Netherlands, talks on a study aiming to assess the association between plasma biomarkers and risk of progression to dementia in a cohort of individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Phosphorylated-tau-181 (pTau181), Aβ42/40, glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) were measured at baseline in 311 individuals with SCD and 252 with MCI, who were followed for an average of 2.7 years. When analyzing the association of individual biomarker concentrations with incident dementia, pTau181 and GFAP levels were both shown to associate with dementia risk, with higher baseline levels predicting an increased risk of progression to dementia. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.